Labo’Life

What Labo’Life does

Labo'Life is a privately-held European pharmaceutical group that develops, manufactures, and distributes micro-immunotherapy medicines — a therapeutic modality using low and ultra-low doses of cytokines (interleukins, interferons, chemokines, growth factors) and Specific Nucleic Acids (SNA®) to modulate immune responses. Founded in October–December 1992 by Christian Foissey with parallel establishments in western France and Consell (Mallorca), Spain, the group operates two GMP-compliant production facilities (Spain and Belgium, with the Belgian site operational since November 2004), an in-house R&D department created in 2007, and wholly-owned subsidiaries across Belgium, Spain, Italy, and France. Its commercial portfolio comprises five sublingual globule medicines authorized in Belgium: 2LEBV®, 2LHERP®, 2LPAPI® (prescription-only) and 2LVERU® and 2LVERU JUNIOR® (over-the-counter), plus the Laboratoires LORICA food-supplement line acquired in 2016.

The group's core technology rests on proprietary SNA® chemistry developed by Dr. Marichal in 1990-1992, delivered via a sublingual globule format that uses numbered capsules (1-10) to ensure sequential administration matching the natural chronology of immune responses. Labo'Life targets recurrent infections, allergies, inflammatory conditions, herpes virus reactivation, and autoimmune-related immune dysregulation. Customers are structured in three layers: healthcare professionals (doctors, therapists, pharmacists) who prescribe; an exclusive European pharmacy network that dispenses both Rx and OTC SKUs; and patients reached via pharmacy channels and dedicated educational blogs (misistemainmune.es, monsystemeimmunitaire.fr).

The business model is a pay-as-you-go, unit-box pharmaceutical sale (30-capsule packs, 3 blisters of 10) routed exclusively through pharmacies across ten European countries (Belgium, Spain, Italy, France, Germany, Austria, Switzerland, Portugal, Luxembourg, Netherlands). Go-to-market is dual-channel: enterprise field sales targeting prescribers through the med.labolife.com professional portal (vademecum, scientific publications, clinical trial information, online pharmacy ordering), and direct-to-consumer education via blogs and social media. The group operates without public listing, ticker, or disclosed funding rounds, sitting under the Spanish holding DIMI (Desarrollo Internacional de Micro-Inmunoterapia S.L.U.).

Name

Labo’Life

Legal name

DESARROLLO INTERNACIONAL DE MICRO-INMUNOTERAPIA S.L.U.

Website

https://labolife.com

Company type

Private

Founded year

1992

Operating status

Operating

Headcount range

51–100 employees

Short description

Labo'Life is a privately-held European pharmaceutical group that develops and distributes micro-immunotherapy medicines — sublingual globules using low-dose cytokines and proprietary Specific Nucleic Acids (SNA®) — exclusively through pharmacies across ten European countries, serving prescribers, pharmacies, and patients with immune-related conditions.

Ownership category

akta.pro rank

Product category

Micro-Immunotherapy Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

akta.pro secondary industries

Immunology & Inflammation Pharmaceuticals (HLAIAAAD), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB), Specialty Pharmacy & Biologics Distribution (CRAOAHAD)

Keywords

• Micro-immunotherapy medicines
• Low-dose immunotherapy
• Immunomodulation pharmaceuticals
• Sublingual globule medicines
• Cytokine-based therapeutics

Headquarters

HQ city

Consell

HQ country

Spain

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Pharmaceutical Medicines Sales: Sale of micro-immunotherapy medicines exclusively through pharmacies. Products include prescription-only medicines (2LEBV, 2LHERP, 2LPAPI) and over-the-counter medicines (2LVERU, 2LVERU JUNIOR). Medicines sold in 30-capsule boxes (3 blisters of 10 capsules each).

Pricing tiers

Go-to-market motion3 records

Distribution channels2 records

Marketing channels6 records

Core offering

Labo'Life develops, manufactures, and distributes micro-immunotherapy medicines that use low and ultra-low doses of immunologically active molecules (cytokines and Specific Nucleic Acids) to modulate the immune system. The portfolio consists of five main medicines (2LEBV, 2LHERP, 2LPAPI, 2LVERU, and 2LVERU JUNIOR) sold as sublingual globules in 30-capsule boxes, available both as prescription-only and over-the-counter products, distributed exclusively through pharmacies across European markets.

Product overview

Labo'Life is a pharmaceutical group and leader in micro-immunotherapy (low-dose immunotherapy). Their product portfolio centers on five main micro-immunotherapy medicines authorized in Belgium: 2LEBV®, 2LHERP®, 2LPAPI®, 2LVERU®, and 2LVERU JUNIOR® - all delivered as sublingual globules in 30-capsule packages. These sequential medicines use low and ultra-low doses of immunologically active molecules (cytokines including interleukins, interferons, chemokines, growth factors; and specific nucleic acids/SNA®) to modulate immune responses. The portfolio includes both prescription-only and over-the-counter formulations targeting different immune-related conditions. Labo'Life also provides healthcare professional resources through their dedicated portal (med.labolife.com), patient education materials, and public health blogs in multiple languages.

Differentiator

Problem solved

Functional benefit

Brands

• Labo'life: Primary brand name for micro-immunotherapy medicines and company operations across European markets.

Products and services

• 2LEBV

Quantifiable outcome

• Medicines help restore immune function balance in conditions where the immune system is involved

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Ten partnerships are on record, tiered minor and core.

• Laboratoires LORICAminorStrategic or Co-development PartnerFood supplements manufacturer integrated into the Labo'Life group in March 2016 as part of the company's diversification strategy to offer solutions for maintaining and recovering health.
• BachiminorOthersHealth organization mentioned in connection with FAGG compliance and Code of Good Practices for the pharmaceutical industry in Belgium.
• MeGeMIT (Medizinische Gesellschaft für Mikroimmuntherapie)coreStrategic or Co-development PartnerMedical society dedicated to professional education in micro-immunotherapy in German-speaking countries.
• AEMI (Asociación Española de Microinmunoterapia)coreStrategic or Co-development PartnerSpanish Association of Micro-Immunotherapy - professional society for training healthcare professionals in micro-immunotherapy.
• IFMi (Institut Français de Micro-immunothérapie)coreStrategic or Co-development PartnerFrench Institute of Micro-Immunotherapy - professional society for training healthcare professionals in France.
• Specialized Healthcare Centers (Hospitals, Clinics, Private Practices)coreStrategic or Co-development PartnerCollaboration with specialized healthcare centers for clinical studies - executing and coordinating interventional and non-interventional clinical studies. Collaboration with medical researchers and prescribers.
• Mallorca Integra Football SchoolminorOthersAssociation providing handicap-appropriate football training programs for people with disabilities as part of social responsibility initiative 'Overcoming Barriers'.
• EducaClownminorOthersNon-profit association creating clown theater performances to educate about immune system health in an engaging way.
• Conversaciones con Hipocrates PlatformminorOthersExchange platform created to reflect on current healthcare challenges and promote a paradigm shift where the human is at the center.
• University of the Balearic Islands (UIB)minorStrategic or Co-development PartnerCollaboration with UIB to promote youth employment and scientific knowledge acquisition. Sponsorship of Biology Olympiad and Mini Olympiad competitions.

Scale indicators6 records

Recent moves16 records

Expansion highlights6 records

Direct peers

• GUNA S.p.A. Italian pharmaceutical company specializing in low-dose medicine and biological regulatory therapy. Most directly comparable peer — same therapeutic modality (low-dose cytokines/SNA-adjacent biology), same pharmacy distribution model, and overlapping geographic presence in Italy/Europe.
• Biologische Heilmittel Heel GmbH: German manufacturer of low-dose, biologically-regulated medicines combining cytokines and homeopathic approaches. Closely comparable technology platform and therapeutic philosophy, with global distribution and similar prescriber/HCP targeting.
• Laboratoires Lehning: French pharmaceutical laboratory producing herbal and homeopathic medicines sold through pharmacies. Comparable pharmacy-channel specialty pharma model in France, with similar HCP-prescribed positioning, though focused on herbal/homeopathic rather than cytokine-based therapy.

Emerging players

• Wala Heilmittel GmbH: German manufacturer of anthroposophic/low-dose medicines and natural cosmetics with strong pharmacy distribution. Comparable philosophy in low-dose biologically-regulated therapy and similar European pharmacy-channel focus; smaller-scale than Labo'Life.
• Leti Pharma: Spanish specialty pharma focused on allergy immunotherapy and dermatology, distributed through pharmacies. Comparable European specialty pharma footprint, similar HCP-prescribing model, and overlapping focus on immune-related conditions though operating in conventional allergen immunotherapy.

Broad incumbents

• Stallergenes Greer: Global specialty immunology company focused on allergen immunotherapy (respiratory allergies, venom). Comparable as a specialty immunology pharma targeting HCPs and pharmacies, but operates in conventional allergen desensitization rather than micro-immunotherapy.
• Vifor Pharma: Swiss specialty pharma focused on iron deficiency, nephrology, and immunology-related therapies. Larger, publicly listed incumbent with broader conventional immunology portfolio and stronger commercial scale; overlapping HCP prescriber base in EU markets.
• Laboratoires Boiron: French global leader in homeopathic medicines, distributed primarily through pharmacies across Europe. Larger, publicly listed (Euronext), broader portfolio, and stronger brand but operates in an adjacent (homeopathic) rather than low-dose immunotherapy category — comparable channel and target HCPs.
• Sanofi (Specialty Care / Immunology): Global pharmaceutical incumbent with a large immunology and specialty care franchise (Dupixent, etc.). Not a direct competitor on low-dose immunotherapy but represents the dominant mainstream immunology option that prescribers may favor over niche micro-immunotherapy in core EU markets.

Regional players

• Laboratoires URGO: French specialty pharma focused on OTC consumer health, including immunity/wellness products sold through pharmacies. Comparable pharmacy-channel distribution and consumer health focus in core EU markets, though not in low-dose immunotherapy.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookes-es.facebook.com/labolife
• LinkedInlinkedin.com/company/labolife
• Xx.com/labolife_es

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Labo’Life